$6.80
0.03[0.44%]
Last update: 4:01PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$6.80
0[0.00%]
| Open6.850 | Close6.850 |
| Vol / Avg.867.420K / 731.764K | Mkt Cap481.404M |
| Day Range6.580 - 6.920 | 52 Wk Range5.770 - 18.890 |
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%
Aclaris Therapeutics Stock (NASDAQ:ACRS), Key Statistics
Aclaris Therapeutics Stock (NASDAQ: ACRS) analysis, key statistics.
Valuation Measures
Enterprise Value
365.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
14.71
Price / Book (mrq)
2.67
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-22.93%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
2.54
Tangible Book value per share
2.44
Total Liabilities (Quarterly)
55.9M
Total Assets
235.6M
Total Liabilities
55.9M
Profitability
Net income Growth
- -
Gross Margin
14.82%
Net Margin
-1582.08%
EBIT Margin
-1727.88%
EBITDA Margin
-1716.21%
Operating Margin
-1727.88%